Publication

Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]

von Martels, J. Z. H., Bourgonje, A. R., Klaassen, M. A. Y., Alkhalifah, H. A. A., Sadaghian Sadabad, M., Vich Vila, A., Gacesa, R., Gabriëls, R. Y., Steinert, R. E., Jansen, B. H., Bulthuis, M. L. C., van Dullemen, H. M., Visschedijk, M. C., Festen, E. A. M., Weersma, R. K., de Vos, P., van Goor, H., Faber, K. N., Harmsen, H. J. M. & Dijkstra, G., May-2020, In : Journal of Crohn's and Colitis. 14, 5, p. 595-607 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

von Martels, J. Z. H., Bourgonje, A. R., Klaassen, M. A. Y., Alkhalifah, H. A. A., Sadaghian Sadabad, M., Vich Vila, A., Gacesa, R., Gabriëls, R. Y., Steinert, R. E., Jansen, B. H., Bulthuis, M. L. C., van Dullemen, H. M., Visschedijk, M. C., Festen, E. A. M., Weersma, R. K., de Vos, P., van Goor, H., Faber, K. N., Harmsen, H. J. M., & Dijkstra, G. (2020). Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]. Journal of Crohn's and Colitis, 14(5), 595-607. https://doi.org/10.1093/ecco-jcc/jjz208

Author

von Martels, Julius Z H ; Bourgonje, Arno R ; Klaassen, Marjolein A Y ; Alkhalifah, Hassan A A ; Sadaghian Sadabad, Mehdi ; Vich Vila, Arnau ; Gacesa, Ranko ; Gabriëls, Ruben Y ; Steinert, Robert E ; Jansen, Bernadien H ; Bulthuis, Marian L C ; van Dullemen, Hendrik M ; Visschedijk, Marijn C ; Festen, Eleonora A M ; Weersma, Rinse K ; de Vos, Paul ; van Goor, Harry ; Faber, Klaas Nico ; Harmsen, Hermie J M ; Dijkstra, Gerard. / Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]. In: Journal of Crohn's and Colitis. 2020 ; Vol. 14, No. 5. pp. 595-607.

Harvard

von Martels, JZH, Bourgonje, AR, Klaassen, MAY, Alkhalifah, HAA, Sadaghian Sadabad, M, Vich Vila, A, Gacesa, R, Gabriëls, RY, Steinert, RE, Jansen, BH, Bulthuis, MLC, van Dullemen, HM, Visschedijk, MC, Festen, EAM, Weersma, RK, de Vos, P, van Goor, H, Faber, KN, Harmsen, HJM & Dijkstra, G 2020, 'Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]', Journal of Crohn's and Colitis, vol. 14, no. 5, pp. 595-607. https://doi.org/10.1093/ecco-jcc/jjz208

Standard

Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]. / von Martels, Julius Z H; Bourgonje, Arno R; Klaassen, Marjolein A Y; Alkhalifah, Hassan A A; Sadaghian Sadabad, Mehdi; Vich Vila, Arnau; Gacesa, Ranko; Gabriëls, Ruben Y; Steinert, Robert E; Jansen, Bernadien H; Bulthuis, Marian L C; van Dullemen, Hendrik M; Visschedijk, Marijn C; Festen, Eleonora A M; Weersma, Rinse K; de Vos, Paul; van Goor, Harry; Faber, Klaas Nico; Harmsen, Hermie J M; Dijkstra, Gerard.

In: Journal of Crohn's and Colitis, Vol. 14, No. 5, 05.2020, p. 595-607.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

von Martels JZH, Bourgonje AR, Klaassen MAY, Alkhalifah HAA, Sadaghian Sadabad M, Vich Vila A et al. Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]. Journal of Crohn's and Colitis. 2020 May;14(5):595-607. https://doi.org/10.1093/ecco-jcc/jjz208


BibTeX

@article{c826567f9e6049aea5cf4d627363f122,
title = "Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]",
abstract = "Background and Aims: Crohn's disease [CD] is characterised by chronic intestinal inflammation and dysbiosis in the gut. Riboflavin [vitamin B2] has anti-inflammatory, antioxidant and microbiome-modulatory properties. Here, we analysed the effect of riboflavin on oxidative stress, markers of inflammation, clinical symptoms, and faecal microbiome in patients with CD. Methods: In this prospective clinical intervention study, patients received 100 mg riboflavin [DSM, Nutritional Products Ltd] daily for 3 weeks. Clinical disease activity [Harvey-Bradshaw Index: HBI], serum biomarkers of inflammation and redox status [plasma free thiols], and faecal microbiome taxonomical composition and functionality [fluorescent in situ hybridisation: FISH; and metagenomic shotgun sequencing: MGS], were analysed before and after riboflavin intervention. Results: In total, 70 patients with CD with varying disease activity were included. Riboflavin supplementation significantly decreased serum levels of inflammatory markers. In patients with low faecal calprotectin [FC] levels, IL-2 decreased, and in patients with high FC levels, C-reactive protein [CRP] was reduced and free thiols significantly increased after supplementation. Moreover, HBI was significantly decreased by riboflavin supplementation. Riboflavin supplementation led to decreased Enterobacteriaceae in patients with low FC levels as determined by FISH; however, MGS analysis showed no effects on diversity, taxonomy, or metabolic pathways of the faecal microbiome. Conclusions: Three weeks of riboflavin supplementation resulted in a reduction in systemic oxidative stress, mixed anti-inflammatory effects, and a reduction in clinical symptoms [HBI]. FISH analysis showed decreased Enterobacteriaceae in patients with CD with low FC levels, though this was not observed in MGS analysis. Our data demonstrate that riboflavin supplementation has a number of anti-inflammatory and anti-oxidant effects in CD. ",
keywords = "Crohn's disease, riboflavin [vitamin B2], clinical intervention study, INFLAMMATORY-BOWEL-DISEASE, FAECALIBACTERIUM-PRAUSNITZII, OXIDATIVE STRESS, ULCERATIVE-COLITIS, VITAMIN B-2, CYTOKINES, BACTERIA, THIOLS, GUT",
author = "{von Martels}, {Julius Z H} and Bourgonje, {Arno R} and Klaassen, {Marjolein A Y} and Alkhalifah, {Hassan A A} and {Sadaghian Sadabad}, Mehdi and {Vich Vila}, Arnau and Ranko Gacesa and Gabri{\"e}ls, {Ruben Y} and Steinert, {Robert E} and Jansen, {Bernadien H} and Bulthuis, {Marian L C} and {van Dullemen}, {Hendrik M} and Visschedijk, {Marijn C} and Festen, {Eleonora A M} and Weersma, {Rinse K} and {de Vos}, Paul and {van Goor}, Harry and Faber, {Klaas Nico} and Harmsen, {Hermie J M} and Gerard Dijkstra",
note = "{\textcopyright} European Crohn{\textquoteright}s and Colitis Organisation (ECCO) 2019.",
year = "2020",
month = may,
doi = "10.1093/ecco-jcc/jjz208",
language = "English",
volume = "14",
pages = "595--607",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]

AU - von Martels, Julius Z H

AU - Bourgonje, Arno R

AU - Klaassen, Marjolein A Y

AU - Alkhalifah, Hassan A A

AU - Sadaghian Sadabad, Mehdi

AU - Vich Vila, Arnau

AU - Gacesa, Ranko

AU - Gabriëls, Ruben Y

AU - Steinert, Robert E

AU - Jansen, Bernadien H

AU - Bulthuis, Marian L C

AU - van Dullemen, Hendrik M

AU - Visschedijk, Marijn C

AU - Festen, Eleonora A M

AU - Weersma, Rinse K

AU - de Vos, Paul

AU - van Goor, Harry

AU - Faber, Klaas Nico

AU - Harmsen, Hermie J M

AU - Dijkstra, Gerard

N1 - © European Crohn’s and Colitis Organisation (ECCO) 2019.

PY - 2020/5

Y1 - 2020/5

N2 - Background and Aims: Crohn's disease [CD] is characterised by chronic intestinal inflammation and dysbiosis in the gut. Riboflavin [vitamin B2] has anti-inflammatory, antioxidant and microbiome-modulatory properties. Here, we analysed the effect of riboflavin on oxidative stress, markers of inflammation, clinical symptoms, and faecal microbiome in patients with CD. Methods: In this prospective clinical intervention study, patients received 100 mg riboflavin [DSM, Nutritional Products Ltd] daily for 3 weeks. Clinical disease activity [Harvey-Bradshaw Index: HBI], serum biomarkers of inflammation and redox status [plasma free thiols], and faecal microbiome taxonomical composition and functionality [fluorescent in situ hybridisation: FISH; and metagenomic shotgun sequencing: MGS], were analysed before and after riboflavin intervention. Results: In total, 70 patients with CD with varying disease activity were included. Riboflavin supplementation significantly decreased serum levels of inflammatory markers. In patients with low faecal calprotectin [FC] levels, IL-2 decreased, and in patients with high FC levels, C-reactive protein [CRP] was reduced and free thiols significantly increased after supplementation. Moreover, HBI was significantly decreased by riboflavin supplementation. Riboflavin supplementation led to decreased Enterobacteriaceae in patients with low FC levels as determined by FISH; however, MGS analysis showed no effects on diversity, taxonomy, or metabolic pathways of the faecal microbiome. Conclusions: Three weeks of riboflavin supplementation resulted in a reduction in systemic oxidative stress, mixed anti-inflammatory effects, and a reduction in clinical symptoms [HBI]. FISH analysis showed decreased Enterobacteriaceae in patients with CD with low FC levels, though this was not observed in MGS analysis. Our data demonstrate that riboflavin supplementation has a number of anti-inflammatory and anti-oxidant effects in CD.

AB - Background and Aims: Crohn's disease [CD] is characterised by chronic intestinal inflammation and dysbiosis in the gut. Riboflavin [vitamin B2] has anti-inflammatory, antioxidant and microbiome-modulatory properties. Here, we analysed the effect of riboflavin on oxidative stress, markers of inflammation, clinical symptoms, and faecal microbiome in patients with CD. Methods: In this prospective clinical intervention study, patients received 100 mg riboflavin [DSM, Nutritional Products Ltd] daily for 3 weeks. Clinical disease activity [Harvey-Bradshaw Index: HBI], serum biomarkers of inflammation and redox status [plasma free thiols], and faecal microbiome taxonomical composition and functionality [fluorescent in situ hybridisation: FISH; and metagenomic shotgun sequencing: MGS], were analysed before and after riboflavin intervention. Results: In total, 70 patients with CD with varying disease activity were included. Riboflavin supplementation significantly decreased serum levels of inflammatory markers. In patients with low faecal calprotectin [FC] levels, IL-2 decreased, and in patients with high FC levels, C-reactive protein [CRP] was reduced and free thiols significantly increased after supplementation. Moreover, HBI was significantly decreased by riboflavin supplementation. Riboflavin supplementation led to decreased Enterobacteriaceae in patients with low FC levels as determined by FISH; however, MGS analysis showed no effects on diversity, taxonomy, or metabolic pathways of the faecal microbiome. Conclusions: Three weeks of riboflavin supplementation resulted in a reduction in systemic oxidative stress, mixed anti-inflammatory effects, and a reduction in clinical symptoms [HBI]. FISH analysis showed decreased Enterobacteriaceae in patients with CD with low FC levels, though this was not observed in MGS analysis. Our data demonstrate that riboflavin supplementation has a number of anti-inflammatory and anti-oxidant effects in CD.

KW - Crohn's disease

KW - riboflavin [vitamin B2]

KW - clinical intervention study

KW - INFLAMMATORY-BOWEL-DISEASE

KW - FAECALIBACTERIUM-PRAUSNITZII

KW - OXIDATIVE STRESS

KW - ULCERATIVE-COLITIS

KW - VITAMIN B-2

KW - CYTOKINES

KW - BACTERIA

KW - THIOLS

KW - GUT

U2 - 10.1093/ecco-jcc/jjz208

DO - 10.1093/ecco-jcc/jjz208

M3 - Article

C2 - 31873717

VL - 14

SP - 595

EP - 607

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 5

ER -

ID: 110879670